Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

Understanding individual differences in the susceptibility to metabolic side effects as a response to antipsychotic therapy is essential to optimize the treatment of schizophrenia. Here we perform genomewide association studies (GWAS) to search for genetic variation affecting the susceptibility to m...

Descripción completa

Detalles Bibliográficos
Autores principales: Adkins, Daniel E., Åberg, Karolina, McClay, Joseph L., Bukszár, József, Zhao, Zhongming, Jia, Peilin, Stroup, T. Scott, Perkins, Diana, McEvoy, Joseph P., Lieberman, Jeffrey A., Sullivan, Patrick F., van den Oord, Edwin J.C.G.
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891163/
https://www.ncbi.nlm.nih.gov/pubmed/20195266
http://dx.doi.org/10.1038/mp.2010.14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891163/
https://www.ncbi.nlm.nih.gov/pubmed/20195266
http://dx.doi.org/10.1038/mp.2010.14

Ejemplares similares